Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Stéphane Bancel & Moderna

9 shared events · Importance 3 · Last updated Aug 29, 2026

Importance
3
Shared Events
9
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
84
Regulatory
Stéphane Bancel: As CEO, Bancel championed the vaccine and highlighted its importance for seniors and the company's future.
Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.
Aug 05, 2026 · 105 articles
84
Tech
Stéphane Bancel: As CEO of Moderna, Bancel is a key figure in the announcement and the company's strategic direction. The trial success is a personal and professional vindication, and he has stated the vaccine could be approved as soon as 2027.
Moderna: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and market cap surging by nearly $40 billion. The trial success validates its mRNA platform and could lead to its entry into the cancer drug market, helping offset declining COVID-19 vaccine sales.
Aug 19, 2026 · 126 articles
65
International
Stéphane Bancel: Stéphane Bancel, CEO of Moderna, pledged urgency and scientific rigor in developing a Bundibugyo vaccine.
Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.
May 21, 2026 · 627 articles
63
Regulatory
Stéphane Bancel: As CEO, Stéphane Bancel announced the approval and highlighted the public health importance, reinforcing leadership.
Moderna: Moderna received FDA approval for its updated COVID-19 vaccines, strengthening its competitive position and revenue outlook for the 2026-2027 season.
Aug 27, 2026 · 6 articles
62
Tech
Stéphane Bancel: Stéphane Bancel>>>, CEO of Moderna>>>, expressed pride in the expanded collaboration, highlighting Moderna's>>> commitment to rapid response to infectious disease threats.
Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.
May 22, 2026 · 36 articles
55
Business
Stéphane Bancel: CEO Stéphane Bancel expressed delight at McDonnell's appointment, citing his industry understanding.
Moderna: Moderna appointed Michael Francis Crotty to its board, gaining financial expertise as it prepares for product launches.
Jul 08, 2026 · 6 articles
45
Regulatory
Stéphane Bancel: Stéphane Bancel, CEO of Moderna, expressed appreciation for the VRBPAC's review and highlighted the potential of mRNA-1010 to offer a new option for seasonal flu prevention, reinforcing the company's commitment to the vaccine.
Moderna: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.
Jun 18, 2026 · 28 articles
0
Regulatory
Stéphane Bancel: Stéphane Bancel, CEO of Moderna, expressed appreciation for the United States — Food and Drug Administration's engagement and agreement to review the vaccine, highlighting the company's goal to make the flu vaccine available to seniors.
Feb 18, 2026 · 9 articles
0
Regulatory
Stéphane Bancel: Stéphane Bancel, Moderna's CEO, expressed disappointment with the United States — Food and Drug Administration's decision, stating it does not further shared goals of innovation.
Feb 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Stéphane Bancel and Moderna interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.